Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lineage Cell Therapeutics (LCTX) Non-Current Receivables (2018 - 2019)

Lineage Cell Therapeutics' Non-Current Receivables history spans 2 years, with the latest figure at $22.9 million for Q2 2019.

  • For Q2 2019, Non-Current Receivables changed N/A year-over-year to $22.9 million; the TTM value through Jun 2019 reached $22.9 million, changed N/A, while the annual FY2018 figure was $22.1 million, N/A changed from the prior year.
  • Non-Current Receivables reached $22.9 million in Q2 2019 per LCTX's latest filing, up from $22.5 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $22.9 million in Q2 2019 to a low of $21.7 million in Q3 2018.